Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys Raises $70M in Series D Financing

NEW YORK – Sequencing technology developer GenapSys said on Thursday that it has raised $70 million in Series D equity financing. The firm is also expanding its board of directors.

Farallon Capital Management and Soleus Capital led the round, joined by additional new investors who were not disclosed.

In a statement, GenapSys said it will use the proceed to further develop its semiconductor-based next-generation sequencing platform. CEO Jason Myers added that the firm would accelerate development of new products, particularly in oncology.

The Redwood City, California-based firm has now raised at least $236 million since 2013, plus $75 million in debt funding last year. The firm offers its benchtop GenapSys Sequencer and a library preparation instrument.

GenapSys is adding Bob Zollars, senior adviser at Frazier Healthcare Partners, and a representative of Farallon Capital to its board. Zollars was previously group president at Cardinal Health. He is also chair of the trustees of Arizona State University.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.